Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 08, 2021 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief...
September 07, 2021 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Participate in Panel Discussion at Women’s Health Innovation Summit

The discussion, Women’s Health Case Study: Optimizing Study Enrollment During the COVID-19 Pandemic, will review the DARE-BVFREE Phase 3 study that was successfully initiated and completed during 2020...
September 01, 2021 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Present at the 13th European Congress on Menopause and Andropause

Presentation will highlight the positive topline results from the Phase 1 clinical trial of DARE-HRT1 Study results demonstrate DARE-HRT1’s ability to co-deliver two different active pharmaceutical...
August 12, 2021 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Reports Second Quarter 2021 Financial Results and Provides a Company Update

SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended June 30, 2021 and...
August 09, 2021 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Announces FDA Acceptance and Priority Review of New Drug Application for DARE-BV1 for the Treatment of Bacterial Vaginosis

Six-month priority review granted for DARE-BV1 with PDUFA target action date set for December 7, 2021.NDA supported by positive data from the DARE-BVFREE Phase 3 study, which demonstrated clinical...
August 05, 2021 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Host Second Quarter 2021 Financial Results and Company Update Conference Call and Webcast on August 12, 2021

SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30...
July 26, 2021 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Present at the 2021 Controlled Release Society Virtual Annual Meeting to be held July 25-29, 2021

Presentation will highlight the positive topline results from the DARE-BVFREE Phase 3 randomized, double-blinded, placebo-controlled clinical trial evaluating Daré’s product candidate DARE-BV1 in...
July 12, 2021 05:45 ET | Source: Daré Bioscience, Inc.

Daré Announces Collaborative Research Agreement (CRADA) for the Pivotal Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Contraceptive

Funding and Clinical Operations Support will be Provided by the National Institutes of Health’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Under the CRADA ...
June 28, 2021 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Announces Positive Phase 1 Results for DARE-HRT1

Results Support Potential as the First Monthly Therapy for both the Vasomotor and the Vaginal Symptoms of Menopause The First Clinical Study Using the Novel Segmented Intravaginal Ring (IVR)...
June 04, 2021 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Present at 2021 BIO Digital

SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it has been selected to deliver a company presentation...